MONTREAL, QUEBEC -- (MARKET WIRE) -- May 22, 2007 -- MethylGene Inc. (TSX: MYG), along with its collaborator Pharmion Corporation (NASDAQ: PHRM), today announced the presentation of three abstracts, one which is an oral presentation for MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from June 1 to June 5, 2007.
